Abstract:Background: Ailanthone, a small compound derived from the bark of Ailanthus altissima (Mill.) Swingle, has several anti-tumour properties. However, the activity and mechanism of ailanthone in colorectal cancer (CRC) remain to be investigated. This study aims to comprehensively investigate the mechanism of ailanthone in the treatment of CRC by employing a combination of network pharmacology, bioinformatics analysis, and molecular biological technique. Methods: The druggability of ailanthone was examined, and its targets were identified using relevant databases. The RNA sequencing data of individuals with CRC obtained from the Cancer Genome Atlas (TCGA) database were analyzed. Utilizing the R programming language, an in-depth investigation of differentially expressed genes was carried out, and the potential target of ailanthone for anti-CRC was found. Through the integration of protein-protein interaction (PPI) network analysis, GO and KEGG enrichment studies to search for the key pathway of the action of Ailanthone. Then, by employing molecular docking verification, flow cytometry, Transwell assays, and Immunofluorescence to corroborate these discoveries. Results: Data regarding pharmacokinetic parameters and 137 target genes for ailanthone were obtained. Leveraging The Cancer Genome Atlas database, information regarding 2,551 differentially expressed genes was extracted. Subsequent analyses, encompassing protein–protein interaction network analysis, survival analysis, functional enrichment analysis, and molecular docking verification, revealed the PI3K/AKT signaling pathway as pivotal mediators of ailanthone against CRC. Additionally, the in vitro experiments indicated that ailanthone substantially affects the cell cycle, induces apoptosis in CRC cells (HCT116 and SW620 cells), and impedes the migration and invasion capabilities of these cells. Immunofluorescence staining showed that ailanthone significantly inhibited the phosphorylation of AKT protein and suppressed the activation of the PI3K/AKT signaling pathway, thereby inhibiting the proliferation and metastasis of CRC cells. Conclusion: Therefore, our findings indicate that Ailanthone exerts anti-CRC effects primarily by inhibiting the activation of the PI3K/AKT pathway. Additionally, we propose that Ailanthone holds potential as a therapeutic agent for the treatment of human CRC.

Ailanthone Induces Cell Cycle Arrest and Apoptosis in Melanoma B16 and A375 Cells

Effects of Matrine on the Proliferation and Apoptosis Induction in Human Malignant Melanoma Cell Line A375

ERK/GSK3β Signaling is Involved in Atractylenolide I-induced Apoptosis and Cell Cycle Arrest in Melanoma Cells.

Ailanthone Inhibits Huh7 Cancer Cell Growth via Cell Cycle Arrest and Apoptosis In Vitro and In Vivo

Synthesis and Evaluation of the Anticancer Activity of Albiziabioside A and Its Analogues As Apoptosis Inducers Against Human Melanoma Cells.

Nitidine Chloride Inhibits Proliferation and Induces Mitochondrial-Mediated Apoptosis of Human Melanoma A375 and A2058 Cells In Vitro

A LY-15, a Novel Cyclic Pentapeptide That Inhibits B16 Cell Proliferation and Migration and Induces Cell Apoptosis.

Piceatannol induced apoptosis through up-regulation of microRNA-181a in melanoma cells

(S)-(-)-n-[2-(3-hydroxy-2-oxo-2,3-dihydro-1h-indol-3-yl)-ethyl]-acetamide Inhibits Melanoma Cell Growth Through Inducing Apoptosis and Autophagy.

Hellebrigenin induces apoptosis by triggering cellular inhibitor of apoptosis 1 and Jun N-terminal kinase pathway in melanoma cells

Isokotomolide A from Cinnamomum Kotoense Induce Melanoma Autophagy and Apoptosis in Vivo and in Vitro.

Apoptotic Effect and Mechanisms of AHPN on Human Skin Malignant Melanoma Cell A375

Ailanthone Increases Cisplatin-induced Apoptosis and Autophagy in Cisplatin Resistance Non-small Cell Lung Cancer Cells through the PI3K/AKT/mTOR Pathway

The Synergistic Mechanism of Chelidonium majus Alkaloids on Melanoma Treatment via a Multi-Strategy Insight

Piperlongumine Induces Apoptosis in Human Melanoma Cells Via Reactive Oxygen Species Mediated Mitochondria Disruption

Cantharidin Induces G2/M Phase Arrest By Inhibition Of Cdc25c And Cyclin A And Triggers Apoptosis Through Reactive Oxygen Species And The Mitochondria-Dependent Pathways Of A375.S2 Human Melanoma Cells

Luteolin inhibits proliferation and induces apoptosis of human melanoma cells in vivo and in vitro by suppressing MMP-2 and MMP-9 through the PI3K/AKT pathway.

Ouabain Exhibited Strong Anticancer Effects in Melanoma Cells via Induction of Apoptosis, G2/M Phase Arrest, and Migration Inhibition

Elucidation of the mechanism of action of ailanthone in the treatment of colorectal cancer: integration of network pharmacology, bioinformatics analysis and experimental validation

Davanone terpenoid inhibits cisplatin-resistant acute myeloid leukemia cancer cell growth by inducing caspase-dependent apoptosis, loss of mitochondrial membrane potential, inhibition of cell migration and invasion and targeting PI3K/AKT/MAPK signalling pathway

Total Glucosides of Paeony Induce Mitochondrial Dysfunction and Apoptosis by Promoting the Degradation of α5-nAChR in Melanoma Cells